Producing Monoclonal Antibody Patents (Class 435/70.21)
-
Publication number: 20130102494Abstract: The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.Type: ApplicationFiled: June 29, 2011Publication date: April 25, 2013Inventor: Alexandra Jouhanneaud
-
Patent number: 8420353Abstract: A humanized antibody is produced by process comprising the steps of: (a) selecting a specificity determining residue (SDR) of the complementarity determining region (CDR) of murine monoclonal antibody heavy chain and light chain variable regions; and (b) grafting said SDR to at least one of the corresponding amino acid sequences in human antibody variable regions.Type: GrantFiled: March 22, 2003Date of Patent: April 16, 2013Assignee: Aprogen, Inc.Inventors: Hyo Jeong Hong, Cheol-Young Maeng, Gi-Hyeok Yang, Meong Hee Jang, Mee Sook Oh, Jin-Soo Song, Young Kug Jang
-
Patent number: 8420348Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.Type: GrantFiled: July 15, 2010Date of Patent: April 16, 2013Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
-
Patent number: 8420085Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of marine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR.Type: GrantFiled: January 18, 2012Date of Patent: April 16, 2013Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia
-
Patent number: 8415113Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.Type: GrantFiled: September 3, 1999Date of Patent: April 9, 2013Assignee: R-Biopharm AGInventors: Hans-Werner Heinrich, Rainer Kleinert, Udo Meyer, Heinz-Jürgen Wagner
-
Patent number: 8399202Abstract: Novel immuno-interactive fragments of the ?C portion of a mammalian inhibin ? subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the ?C portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: March 30, 2009Date of Patent: March 19, 2013Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 8399207Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.Type: GrantFiled: January 3, 2011Date of Patent: March 19, 2013Assignee: Maine Medical CenterInventors: Lucy Liaw, Ah-Kau Ng
-
Publication number: 20130064851Abstract: The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria.Type: ApplicationFiled: November 12, 2012Publication date: March 14, 2013Applicant: VACCINE RESEARCH INTERNATIONAL PLCInventor: Vaccine Research International PLC
-
Publication number: 20130045209Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human Wnt(s) are provided. A conserved domain within Wnt that is suitable as a target for anti-cancer agents is also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: ApplicationFiled: January 12, 2011Publication date: February 21, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventor: Austin L. Gurney
-
Publication number: 20130039850Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.Type: ApplicationFiled: July 9, 2012Publication date: February 14, 2013Applicant: GENPHARM INTERNATIONAL, INC.Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
-
Patent number: 8367356Abstract: The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.Type: GrantFiled: August 15, 2007Date of Patent: February 5, 2013Assignee: Beijing Cotimes Biotech Co., Ltd.Inventors: Enyun Shen, Zheng Yu, Min Zhou, Fei Guo
-
Patent number: 8367374Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: January 22, 2004Date of Patent: February 5, 2013Assignee: Roche GlycArt AGInventors: Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter
-
Patent number: 8361461Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor.Type: GrantFiled: July 21, 2006Date of Patent: January 29, 2013Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaïa
-
Publication number: 20130022957Abstract: A method of increasing animal cell growth and monoclonal antibody production in an animal cell or cell culture includes the use of ultrasound at a frequency greater than about 1 MHz.Type: ApplicationFiled: September 21, 2011Publication date: January 24, 2013Applicant: INTELLIGENTNANO INC.Inventors: Jie CHEN, James XING, Woon T. ANG
-
Publication number: 20130017201Abstract: The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of B. anthracis. It also relates to process for preparation of said mAb, and to pharmaceutical preparations, anthrax diagnostic tool, in-vivo diagnostic imaging tool comprising said mAb. It also relates to genetically modified mAb, and method for prophylaxis against anthrax disease comprising administration of mAb or genetically modified mAb of present invention.Type: ApplicationFiled: March 22, 2011Publication date: January 17, 2013Inventors: Rakesh Bhatnagar, Parul Kulshreshtha
-
Patent number: 8349569Abstract: A method for measuring a fibronectin fragment which is easy to handle and has excellent measuring accuracy, specificity and reproducibility is provided. An anti-fibronectin fragment monoclonal antibody which reacts with a human fibronectin fragment but does not react with human fibronectin, a measuring reagent containing the monoclonal antibody, a method for measuring a fibronectin fragment which uses the monoclonal antibody and a hybridoma which produces the monoclonal antibody are provided.Type: GrantFiled: March 31, 2010Date of Patent: January 8, 2013Assignee: Takara Bio Inc.Inventors: Chika Kato, Yuka Sano, Kyoko Kamihagi, Ikunoshin Kato
-
Patent number: 8337861Abstract: The present invention comprises methods for enhancing the immunogenicity of a bacterial vaccine vector and an antigen by passaging the bacterial vaccine vector through an animal.Type: GrantFiled: January 8, 2004Date of Patent: December 25, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Yvonne Paterson, Christian Peters
-
Publication number: 20120321653Abstract: The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and polynucleotides coding for these polypeptides, for the production of immunogenic compositions based on exosomes or DNA, to screen protein interactions. The present invention also concerns exploiting the properties of exosomes comprising a polypeptide of the invention and immunogenic compositions of the invention in immunology. The present invention concerns the use of exosomes comprising a polypeptide of the invention as a diagnostic tool.Type: ApplicationFiled: September 23, 2010Publication date: December 20, 2012Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Robert Zaine El Abiddine Mamoun
-
Patent number: 8329886Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: May 16, 2012Date of Patent: December 11, 2012Assignees: Hoffman-La Roche Inc., Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Publication number: 20120301923Abstract: The present disclosure provides systems and methods of using a semipermeable membrane in a dialysis fermenter as a separation layer between a cell-containing liquid culture medium and a non-cell-containing dialysis medium. In some embodiments, the semipermeable membrane may have a molecular cut-off of 15 kDa to 50 kDa. The instant disclosure also provides a dialysis fermenter with compartments for cell-containing culture medium, non-cell-containing nutrient solution as well as an exchange unit having a semipermeable membrane, wherein mass transfer takes place between the culture medium and the dialysis medium by means of diffusion and/or ultrafiltration. Methods for culturing cells are also disclosed.Type: ApplicationFiled: May 24, 2012Publication date: November 29, 2012Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Artur Hoffmann, Max Lechner, Christoph Reese
-
Patent number: 8309315Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: GrantFiled: August 25, 2008Date of Patent: November 13, 2012Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research CenterInventors: Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
-
Patent number: 8298836Abstract: Disclosed is an isolated polynucleotide encoding a modified Fab' antibody, which includes an Fd chain and an L chain with the Fd chain including a CH1 region and the L chain including a CL region, wherein the modified Fab' antibody further includes a cysteine for binding to a fluorescent dye, and the polynucleotide includes an Fd chain coding region and an L chain coding region linked therebetween in a manner that will allow expression of the modified Fab' antibody. Also disclosed are an expression vector containin the isolated polynucleotide, an isolated transformed host cell containing the expression vector, and a cell culture including the transformed host cell.Type: GrantFiled: November 2, 2004Date of Patent: October 30, 2012Assignee: Hamamatsu Photonics K.K.Inventors: Sunao Hisada, Yukiko Ito, Hiroyuki Matsumoto, Kiyohito Shimura, Kenichi Kasai
-
Publication number: 20120271034Abstract: Provided are antigenic determinants recognized by anti-human death receptor DR5 monoclonal antibody AD5-10, derivatives and uses thereof. The antigenic determinants have the amino acid sequence of LITQQDLAPAARA, wherein the core polypeptide is QDLAP. The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants and derivatives thereof can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine. Their nucleotide encoding sequences can be used for preparing antisense nucleotides and small molecular ribonucleotides for treating and preventing tumor and/or AIDS and the like.Type: ApplicationFiled: April 3, 2009Publication date: October 25, 2012Applicant: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADE MY OF MEDICAL SCIENCESInventors: Yanxin Liu, Peng Zhang, Yong Zheng, Dexian Zheng
-
Publication number: 20120263724Abstract: Immunogenic Escherichia coli O157:H7 (0157) proteins expressed during infection of a mammal, are described. In particular, 0157 proteins expressed specifically in vivo during human and cattle infection were identified. These proteins, mapped to the backbone, O-islands (OIs) and pO157. Because these-proteins are expressed during infection, and might help pathogens adapt to and counter hostile in vivo environments, those proteins identified in this study are useful as targets for drug and vaccine development. Also, such proteins are useful as markers of 0157 infection in stool specimens. Also described are methods of identifying immunogenic proteins.Type: ApplicationFiled: April 20, 2006Publication date: October 18, 2012Inventors: Manohar John, Indira T. Kudva, Stephen B. Calderwood, Bryan Krastins, David A. Sarracino
-
Patent number: 8278424Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: April 26, 2011Date of Patent: October 2, 2012Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Publication number: 20120244076Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.Type: ApplicationFiled: May 22, 2012Publication date: September 27, 2012Inventors: Robert J. HICKEY, Linda H. MALKAS, Lauren SCHNAPER
-
Patent number: 8268593Abstract: Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer's disease and A? peptide associated diseases are also described.Type: GrantFiled: April 5, 2010Date of Patent: September 18, 2012Assignee: Rinat Neuroscience Corp.Inventors: Arnon Rosenthal, Jaume Pons, Wei-Hsien Ho, Jan Markus Grimm
-
Patent number: 8268973Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: GrantFiled: July 20, 2011Date of Patent: September 18, 2012Assignee: Onclave TherapeuticsInventors: Dale B. Schenk, Peter A. Seubert, José Saldanha
-
Patent number: 8268592Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: July 17, 2009Date of Patent: September 18, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Patent number: 8247188Abstract: The disclosed invention relates to monoclonal antibodies (MAbs) which recognize human fatty acid synthase (hFAS) and are distinct from previously known anti-hFAS antibodies. Compositions, devices and kits comprising the MAbs are provided along with methods of using the MAbs in a variety of applications.Type: GrantFiled: August 17, 2006Date of Patent: August 21, 2012Assignee: Fasgen Diagnostics, LLCInventors: Susan Medghalchi, Jennifer L. Aldrich
-
Publication number: 20120201829Abstract: The present invention includes a human monoclonal antibody specific for the alpha-toxin of S. aureus, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention includes methods for producing the monoclonal antibody. In addition, the present invention includes pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding the antibody. Further, the present invention includes the use of the monoclonal antibody for treating or preventing abscess formation.Type: ApplicationFiled: August 10, 2010Publication date: August 9, 2012Inventors: Michael Rudolf, Holger Koch
-
Patent number: 8236530Abstract: A significantly increased amount of a monoclonal antibody is obtained from the culture medium of recombinant hybridoma prepared by introducing genes encoding a protein identical to the immunoglobulin heavy chain polypeptide of the specific monoclonal antibody into an immortalized B cell (hybridoma) producing the monoclonal antibody.Type: GrantFiled: September 28, 2005Date of Patent: August 7, 2012Assignees: Japan Tobacco Inc., Abgenix, Inc.Inventors: Chihiro Kusunoki, Atsushi Fukushima
-
Publication number: 20120191163Abstract: A method of manipulating a living cell is disclosed. The method comprises, directing a pulsed optical field to at least one conductive nanoparticle present in the vicinity of the cell, so as to generate cavitations at or near the conductive nanoparticle at sufficient amount to effect at least one cell modification selected from the group consisting of cell-damage and cell-fusion.Type: ApplicationFiled: January 19, 2012Publication date: July 26, 2012Applicant: Technion Research & Development Foundation Ltd.Inventors: Dvir Yelin, Limor Minai, Daniella Yeheskely-Hayon
-
Publication number: 20120183997Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.Type: ApplicationFiled: February 24, 2012Publication date: July 19, 2012Applicant: Seattle Genetics, Inc.Inventors: STEPHEN C. ALLEY, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
-
Patent number: 8216807Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.Type: GrantFiled: February 11, 2011Date of Patent: July 10, 2012Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
-
Publication number: 20120171216Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: October 13, 2011Publication date: July 5, 2012Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Patent number: 8206951Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: July 15, 2011Date of Patent: June 26, 2012Assignee: MedImmune, LLCInventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Publication number: 20120157663Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.Type: ApplicationFiled: August 24, 2011Publication date: June 21, 2012Inventors: Takachika AZUMA, Hisao TAKIZAWA
-
Publication number: 20120141519Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.Type: ApplicationFiled: May 28, 2010Publication date: June 7, 2012Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
-
Publication number: 20120135003Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: November 22, 2011Publication date: May 31, 2012Applicant: SBI Biotech, Ltd.Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Publication number: 20120135018Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG anti-body. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.Type: ApplicationFiled: April 28, 2010Publication date: May 31, 2012Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
-
Patent number: 8187602Abstract: The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.Type: GrantFiled: April 19, 2010Date of Patent: May 29, 2012Assignee: Amateraspharma Inc.Inventors: Takeshi Goto, Shuji Sato, Kazuhisa Ono, Seiko Shigeta, Seiji Kawamoto, Shigeru Goto
-
Patent number: 8187884Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible. The production of antibodies that bind specifically to antigens from cell populations in which the antibody molecules have been diversified by the enhancement of somatic homologous recombination is made possible by using an appropriate selection method (for example, beads coated with antigen and the like).Type: GrantFiled: June 10, 2010Date of Patent: May 29, 2012Assignees: Riken, Chiome Bioscience, Inc.Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20120115151Abstract: The present invention concerns a method of testing a subject thought to be predisposed to having a metastatic cancer which comprises: analyzing a biological sample from said subject for detecting the presence of a p53 isoform selected from the group consisting of ?133p53, ?133p53? and ?133p53?, the presence of said p53 isoform being indicative of a metastatic cancer.Type: ApplicationFiled: June 30, 2010Publication date: May 10, 2012Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre Roux, Gilles Gadea, Stephane Vinot, Christelle Anguille, Jean-Christophe Bourbon, Kenneth Fernandes
-
Patent number: 8168409Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: November 24, 2010Date of Patent: May 1, 2012Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 8163285Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.Type: GrantFiled: October 27, 2008Date of Patent: April 24, 2012Assignee: Novartis AGInventors: Carmen Barske, Stefan Frentzel, Anis Khusro Mir, Martin E. Schwab, Alessandra Vitaliti Garami
-
Patent number: 8163886Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.Type: GrantFiled: December 20, 2007Date of Patent: April 24, 2012Assignee: EMD Millipore CorporationInventor: Wilson Moya
-
Patent number: 8163288Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: GrantFiled: June 29, 2010Date of Patent: April 24, 2012Assignee: Absynth Biologics LimitedInventors: Simon J. Foster, Jorge Garcia-Lara
-
Patent number: RE43823Abstract: Compositions are provided that comprise antibody against coreceptors for human immunodeficiency virus such as CCR5 and CXCR4. In particular, monoclonal human antibodies against human CCR5 are provided that bind to CCR5 with high affinity and are capable of inhibiting HIV infection at low concentrations. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, for screening drugs, and for diagnosing diseases or conditions associated with interactions with HIV coreceptors.Type: GrantFiled: November 18, 2011Date of Patent: November 20, 2012Assignee: Genetastix CorporationInventors: Shaobing Hua, Michelle Haynes Pauling, Li Zhu